| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Tarperprumig | ALXN-1820 | Phase 2 Clinical | Alexion Pharmaceuticals Inc | Anemia, Sickle Cell; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | Details |
| NM-5072 | NM5072; NM-5072 | Phase 1 Clinical | NovelMed Therapeutics Inc | Atypical Hemolytic Uremic Syndrome; Eye Diseases; Hemoglobinuria, Paroxysmal | Details |